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Results. The most frequent keloid site was ear lobe (n: 10). Three cases were lost and excluded during the follow up. Response to
therapy was shown in 13 cases (76.5%).
Complete response. 9 (53%), Hypertrophic scars: 4, and relapses: 4 (23.5%, mean time: 1 year). After 2 years of follow up, 12 cases
continued as responders (90.3%), 9 cases (69.3%) after 3 years and after 4 years, 8 (61.5%) are still in response. Consequences were
pain and pruritus in 5 patients (29.4%).
Conclusion. Post-excision radiotherapy seems to be an optimum technique in handling keloids. However, electron therapy using
a spoiler needs to be further evaluated in practice. Our results seem to be similar to those obtained with other techniques, such
a Brachytherapy or superﬁcial X-ray.
http://dx.doi.org/10.1016/j.rpor.2013.03.608
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Introduction. Volumetric Modulated Arc Therapy is the last generation of arch dynamic therapy, a technology that allows better
dose conformation, signiﬁcant reduction of treatment time, improvement of patient comfort, reduce the risk of patientmovement
during treatment and reduce the dose received by the organs at risk.
Objective. The purpose of this paper is to present the case of a bilateral ductal invasive carcinoma treated with adjuvant radio-
therapy using VMAT in order to demonstrate its dosimetric advantages.
Materials and methods. The patient is a 62 year old woman diagnosed in April 2011 with Bilateral Ductal Invasive Breast Carcinoma,
cT4 cN1 M0 (Stage IIIB). The patient receives neoadjuvant chemotherapy (Adriamicine-Ciclofosfamide×4, followed by weekly
Paclitaxel×12), followed by a bilateral radical mastectomy and axillary lymph node resection. After that, the woman was sent
to our department to receive adjuvant radiotherapy. Given the characteristics of the target volume, radiotherapy planning with
VMAT technique was chosen in order to reduce the dose received by the organs at risk.
Results. Our PTV was both chest walls and bilateral axillary and supraclavicular lymph node chains. The total dose was 50Gy
delivered in 25 fractions with a daily dose of 200 cGy. Planning was carried out using Monaco 2.03 with an full arch, 154 segments
and 737.24 monitor units. In ﬁgure 1 shows the Dose-Volume histogram, the isodoses in an axial, coronal and 3D reconstruction
and the isodose of 20Gy. Table 1 shows the mean dose to the PTVs and the organs at risk. PTV right chest wall (Doses mean
“Dm”: 50.80Gy); PTV left chest wall (Dm: 51.06Gy); PTV right node (Dm: 50.68Gy); PTV left node (Dm: 50.78Gy) and mean dose in
the most important organs at risk: Heart, (Dm: 12.94Gy and V20: 17.82Gy); right lung, (Dm: 11.96Gy and V20: 18.75Gy) and left
lung, (Dm: 12.08Gy and V20: 19.33Gy). Treatment was carried out using an Elekta Synergy linear accelerator.
Conclusion. Using VMAT, we can administer our planned dose to large PTVs (in this case both chest walls, axillary and supracla-
vicular chains) and exclude organs at risk (heart and lungs) from the dose of 20Gy.
http://dx.doi.org/10.1016/j.rpor.2013.03.609
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Introduction.Weknowobjectivewaysof determining the locationof the radiotherapy treatment isocenter (Image-GuidedRadiation
Therapy), but in many hospitals this is done through portal imaging (2D–2D) supervised by specialists. Without the aid of these
technological means, we can question the inﬂuence exerted by the specialists’ subjectivity on the correct placement of the
isocenter.
Objectives. Observe whether there is a signiﬁcant inﬂuence on the coordinate shifts performed by different specialists for different
tumor sites.
Methods. We studied 552 patients treated with a Siemens Primus linear accelerator. The corrections performed on the treatment
isocenter were analyzed in relation to the position established in the planning stage. These corrections may vary in subsequent
days of treatment giving us a history of not only the variability inherent to the conditions of the patients but also of the variability
due to the degree of subjectivity of the radiation oncologist. Corrections were made based on the realization of portal imaging
tests within the ﬁrst three days of treatment, and then on a weekly basis. We calculated corrections in each of the Cartesian axes
(Dx, Dy and Dz) made for each patient. We also analyzed the maximum coordinate shifts. After grouping patients by pathology
and radiation oncologist, we performed a statistical analysis to test for signiﬁcant differences among different specialists in
determining the isocenter.
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Results. We found no signiﬁcant differences in the value of the corrections made by each expert on the isocenter (p>0.05 ANOVA
test) for various diseases.
Conclusions. The value of the coordinate shifts resulting from the relocation of the isocenter by performing portal imaging does
not depend on the radiation oncologist according to our analysis. It may be concluded that the method is “objective”, although
nothing can be stated about the suitability of the corrections in terms of size and direction regarding algorithmic methods of
image processing.
http://dx.doi.org/10.1016/j.rpor.2013.03.610
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Introduction. The pelvic irradiation is needed in several pathologies and is, in general, planned with high energy (15–18MV) photon
beams. However, since 6MV photon beams were accepted as an effective energy choice for most IMRT cases, more and more
radiotherapy services are acquiring linear accelerators without these high energy photon beams. Besides the issues concerning
increased leakage and secondaryneutrondose for thepatientswhenusinghigh-energyphotons, this choice canhave a signiﬁcant
economical impact in departments or countries with limited resources.
Objectives. The purpose of this work was to evaluate the use of 6MV beams to treat pelvic volumes, a situation in which
traditionally higher energies (15 or 18MV) are used.
Materials and methods. We selected 10 patients with rectum carcinoma. PTV and OAR volumes were delineated and alternative
plans (6MV vs. 18MV) were produced for two techniques: complex 3DCRT (multiple beams with segments) and IMRT (50Gy/25F).
The plans were evaluated and compared in terms of PTV coverage, dose to OAR and mean dose to the whole body.
Results. No signiﬁcant differences were found between 6MV and 18MV plans in terms of PTV coverage. Concerning the OAR,
we found a consistent increment in the mean dose to the femoral heads (average of 1.5Gy/25F) and whole body (average of
1.2Gy/25F) when using 6MV.
Conclusions. If complex 3DCRT techniques are used in pelvic irradiation, like in rectum cases, the use of 6MV beams is possible
and competitive in quality when compared to high-energy beams. Target and OAR volumes should be delineated for correct plan
evaluation. The option of completely waive high energy beams can only be taken if the department has the human and technical
resources to treat all these patients with complex 3D techniques.
http://dx.doi.org/10.1016/j.rpor.2013.03.611
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Stereotactic body radiotherapy (SBRT) treatment provides local disease control and pain relief with minimal side effects in the
treatment of spine metastases. The PTV surrounds the cord (very close to it), as a cylindrical shell wrapping around it. Spine SBRT
maintains the cord dose within tolerance as well as covers PTV suitably. The treatment time per fraction in SBRT can be improved
signiﬁcantly using volumetric modulated arc therapy (VMAT). This work shows our ﬁrst experience in the treatment of spine
metastases combining VMAT and SBRT techniques. The case reported consists on a spine lesion located in L4. PTV is expanded
from CTV with a 3mm margin. The prescription for SBRT treatment is 24Gy, delivered in 3 alternate-day fractions of 8Gy. 90%
of PTV should be covered with 100% of the prescription dose. Dose constraints for the cord are Dmax<14Gy and V10<10%.
Treatment is delivered with an Elekta Synergy linear accelerator, using VMAT technique. The plan consists in 2 full arcs resulting
in 432 control points. Plan quality is evaluated using DVH parameters: D99%, D95%, D90%, Dmean, D10%, D5% and D1%. Daily
cone-beamCTcorrections areperformedas image-guided radiation therapy technique tominimize geometric uncertainties. Valid
VMAT plan is generated by the TPS. Dose distribution wraps the cord, preserving it and covering the PTV with D90%=24.4Gy.
DVH parameters are D99%=16.6Gy, D95%=21.6Gy, Dmean=26.4Gy, D10%=27.9Gy, D5%=28.1Gy and D1%=28.4Gy. Maximum
dose in cord is 13.4Gy and V10=4.5Gy. This work presents the ﬁrst spine metastases case treated in our institution combining
SBRT and VMAT treatment techniques. Dosimetric parameters are consistent with those in literature, and cord dose preserve
the imposed constraints.
http://dx.doi.org/10.1016/j.rpor.2013.03.612
